Look back at pharma news in the week to June 26, 2020
By Barbara Obstoj-Cardwell. Editor
Last week saw Gilead Sciences reveal it was buying a 49.9% stake in immune-oncology-focussed Pionyr Immunotherapeutics and taking an option to acquire the rest of the company. On the regulatory front, India’s Glenmark Pharmaceuticals gained marketing approval for its favipiravir product FabiFlu on its domestic market for the treatment of COVID-19. Also, AbbVie and Allergan received a complete response letter (CRL) from the US Food and Drug Administration for their DARPin therapy abicipar pegol. Deal-making news included Sanofi entering a multi-billion licensing accord with USA-based Translate Bio for its infectious disease vaccines, and Dutch biotech uniQure entered into a deal with Australian CSL Limited’s CSL Behring unit on its hemophilia B drug etranacogene dezaparvovec.
Gilead takes a punt on pre-clinical Pionyr
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze